BENEO is currently showcasing its expertise in pharmaceutical ingredients — particularly excipients — at CPHI Milan.
The star of the show will be BENEO's pharmaceutical excipient, galenIQ, which can be incorporated into a range of OSD forms to improve their taste.
According to BENEO, the demand for palatable dosage forms has seen a significant increase in recent years, with the pharmaceutical industry taking a specific interest in patient centricity.
The Head of Pharmaceutical Technology at BENEO, Oliver Luhn, commented: "When formulating an OSD, palatability plays a significant role. Combining an appealing taste profile with excellent technical properties can make a huge difference. As a result, we're seeing a growing market interest in easy-to-process products such as our bulk sweetener galenIQ."
What is galenIQ?
Derived from sugar beet, galenIQ is a sweetening excipient with a similar profile to sucrose — though it is non-cariogenic.
The product, according to BENEO, also has great flow/mixing properties and high compactability, which enhances the stability of pharmaceutical OSDs.
galenIQ is also GMP-manufactured, and is available in various grades to suit different dosage forms.
Maj-Britt Cepok, Head of Business Development Pharma at BENEO, commented: “On the one hand, dosage forms are getting more diverse. On the other hand, in line with a more consumer-centric approach, there’s a stronger focus on how to make taking medicines as comfortable and convenient as possible."
"An appealing flavour can have a significant influence on patient compliance and, with galenIQ, manufacturers have access to a reliable solution that can help them to achieve a well-balanced sensory profile.”
A versatile excipient for enhanced patient centricity
BENEO's sweetening excipient can be incorporated into a vast range of dosage forms, including chewable tablets, medicated losenges, sachets and more.
Michael Black, Head of Sales (Pharma) at BENEO, added: "We're keen to discuss how galenIQ can address sensory challenges in the development process, such as bitter notes. Bitterness is commonly associated with a large number of active pharmaceutical ingredients, so mitigating this issue is important."
Attendees are invited to visit Booth 6C57 to learn more about galenIQ.
